PhaseII study of trancatheter arterial chemoembolizaion with miriplatin for hepatocellular carcinoma -Compared with retrospective historical cohort study with epirubicin hydrochloride- - PhaseII study of TACE with miriplatin for HCC

ara Medical University, Department of Radiology0 个研究点目标入组 33 人开始时间: 2011年3月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who have medical history of hypersensitivity of platinum-containing drug. 2) Patients who have medical history of hypersensitivity of iodine containing agent and/or contrast material. 3) Extrahepatic metastasis. 4) Bile duct invasion or vascular invasion. 5) Patients after HCC is ruptured. 6) Patients who have medical history of surgical reconstruction of the biliary tract or endoscopic biliary treatment. 7) Patients who have moderate or severe pleural effusion or ascites to be unresponsive to therapy. 8) Severe arterioportal shunt or arteriovenous shunt in the liver. 9) Patients with following severe complicating disease. - Patients who are difficult to control heart failure, angina or arrhythmia despite treatment - Cardiac infarction within 6 months of onset - Renal failure - Active infections(except viral hepatitis) - Active gastrointestinal bleeding - Active duplicative cancer - Hepatic encephalopathy or severe mental illness 10) Patients who are pregnant, lactating or are suspected to be pregnant. 11) Patients who are concluded to be inappropriate to participate in this study safety by their physicians.

发起方

ara Medical University, Department of Radiology